Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center
about
Inflammatory bowel disease: an increased risk factor for neurologic complicationsAdverse events in IBD: to stop or continue immune suppressant and biologic treatmentA medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Management of arthropathy in inflammatory bowel diseases.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseasePrevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.Translational research and efficacy of biologics in Crohn's disease: a cautionary tale.Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?Natalizumab in Crohn's disease: past and future areas of applicability.Natalizumab in the treatment of Crohn's disease patients.What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients.Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
P2860
Q27690759-DB869530-AB54-4D73-B0CC-6ED22EB416A4Q34073191-DCF89213-3AB0-4246-86EA-FABF1DF6FC04Q34353032-612D70A2-8FE5-48A0-8255-991C3F4378D7Q35091366-BEB08B24-E977-4157-BD21-66BB9CF3FF35Q35559305-2DDAE67F-6255-470F-91EA-36A1E3CFFE95Q36697972-12FC29B4-C05B-4384-A55C-13442B756F5AQ37098441-DA508096-0E86-4ADE-9784-5E9A42D34298Q38130407-93CEA5E4-8C47-4D02-8B2C-E4BE09FA720DQ38177338-52A606BC-22CC-4A83-978F-61B65B8BF21FQ38337716-BBF5FDED-A185-4640-944C-001EF76F70C8Q38356722-6BD2451D-D767-4546-9591-43EDEFB1581BQ38612843-B31C35F2-61F7-4741-89D3-640235A7AFCEQ38849974-3782CBD5-0ED8-466B-A8C5-8051A3EE4D5AQ42364630-521DE3A5-E901-4500-8F9E-E428EB4EA1C1Q42430716-CB2FBE05-8F7A-47C8-900F-24F84C4A0EF1Q54746034-F78152AD-68FB-4AC2-BF3F-576A7B894055
P2860
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Natalizumab in Crohn's disease ...... lammatory bowel disease center
@ast
Natalizumab in Crohn's disease ...... lammatory bowel disease center
@en
type
label
Natalizumab in Crohn's disease ...... lammatory bowel disease center
@ast
Natalizumab in Crohn's disease ...... lammatory bowel disease center
@en
prefLabel
Natalizumab in Crohn's disease ...... lammatory bowel disease center
@ast
Natalizumab in Crohn's disease ...... lammatory bowel disease center
@en
P2093
P2860
P1476
Natalizumab in Crohn's disease ...... lammatory bowel disease center
@en
P2093
Chase Correia
David T Rubin
John Melek
Kian Keyashian
Russell D Cohen
Stephen B Hanauer
P2860
P304
P356
10.1097/MIB.0B013E31827EEA78
P577
2013-03-01T00:00:00Z